Kornimate/medical-research-clean huggingface dataset:
idiopathic pulmonary fibrosis job exposures study

Conditions: IPF; Idiopathic Pulmonary Fibrosis

Summary: a case-control study to investigate whether job exposures are an under-recognized cause of idiopathic pulmonary fibrosis (ipf) using an interview to collect information about previous jobs and a blood test to investigate genetic susceptibility.

idiopathic pulmonary fibrosis (ipf) is a scarring lung disease. it damages the air sacs that allow oxygen to be transferred into the blood and transported to vital organs. these changes make people with ipf cough and feel short of breath. it not known what causes the damage. people who get ipf are usually older than 40; it's a very serious illness that cannot be cured and gets worse over time. statistics show that ipf is becoming more common in the uk but it's not known why. it can be difficult for doctors to tell if someone has ipf or another disease called asbestosis.

Eligibility criteria:
for cases inclusion criteria: * new diagnosis of ipf between february 2017 and october 2019 exclusion criteria: * unable to give informed consent * ever worked outside of the uk for controls inclusion criteria: * new outpatient department attendee between february 2017 and october 2019 exclusion criteria: * unable to give informed consent * ever worked outside of the uk (does not include work outside the uk by members of the armed forces or merchant navy) * diagnosis of ipf

Keywords: idiopathic pulmonary fibrosis
aquablation vs. holmium laser enucleation of the prostate in the treatment of benign prostatic hyperplasia in medium to large size prostates

Conditions: Benign Prostatic Hyperplasia (BPH)

Summary: benign prostatic hyperplasia (bph) is one of the most common diseases in men. as bph progresses, surgical treatments often become necessary. holmium enucleation of the prostate (holep) is an established procedure in the surgical treatment of bph, especially for medium to large prostates. the long learning curve, the length of surgery, and expensive equipment still limit the availability of holep to a few specialized centers. recently, a new method for treating bph called aquablation has become commercially available. this technique uses real-time ultrasound imaging in combination with a robotic high-pressure water jet programmed and guided by the surgeon to resect prostate tissue. a rct has shown functional results similar to transurethral resection of the prostate (turp) for small to medium size prostates . however, so far there are no controlled studies assessing whether aquablation provides patient reported and functional outcomes that are non-inferior compared to holep in medium size to large prostates (the latter cannot be operated by turp due to its size limitations). as aquablation offers some obvious advantages compared to holep regarding learning curve and operation time, the aim of this study is to test whether efficacy and safety of aquablation are non- inferior compared to holep in patients with medium to large size prostates, which would clearly support the use of aquablation and change everyday clinical practice.


Eligibility criteria:
inclusion criteria: * men ≥45 years of age * patient must be a candidate for holep * refractory to medical therapy or patient is not willing to consider (further) medical treatment * patient has a prostate size of at least 50 ml and not more than 150ml, measured by transrectal ultrasound (trus) * ipss ≥12 * qol≥3 * qmax ≤ 15 ml/s with a minimum voided volume ≥ 125 ml or patient in urinary retention * written informed consent exclusion criteria: * neurogenic lower urinary tract dysfunction * urethral stenosis * preinterventionally proven adenocarcinoma of the prostate * nickel allergy * not able to complete questionnaires due to cognitive or thought disorders * language skills insufficient for informed consent and / or completion of questionnaires
single-blind, dose-ranging study of novel swine influenza virus vaccine in japanese pediatric subjects

Conditions: Swine-Origin Influenza A H1N1 Virus

Summary: this study is to identify the preferred vaccine dosage (of antigen and adjuvant) and schedule (one or two administrations) of the cell-derived h1n1sw monovalent vaccine in healthy children/adolescents based on european medicines agency's committee for medicinal products for human use (emea/chmp) criteria, and safety and tolerability.

this is a multi-center, randomized, single-blind, dose-ranging study. subjects were randomized at a 1:1 ratio to receive either 3.75μg of cell-derived h1n1sw vaccine formulated in half (i.e., half the content of the european-licensed adjuvanted seasonal influenza vaccine) mf59 adjuvant (3.75_halfmf59) or 7.5μg of cell-derived h1n1sw vaccine formulated with full mf59 (7.5_fullmf59). subjects were not informed of their allocated doses. two vaccinations were administered im three weeks apart. subjects in both the vaccine groups were stratified into three age strata: 6 to 35 months, 3 to 8 years and 9 to 19 years. blood samples were collected at day 1 (baseline), three weeks after the first vaccination (day 22) and three weeks after the second vaccination (day 43). sera were tested by hemagglutination inhibition (hi) and microneutralization (mn) assays. local and systemic reactions were collected for the first week following each injection using diary card (i.e., day 1 to day 7 and day 22 to day 28). all adverse events (ae), serious adverse events (sae), and aes that led to withdrawal from the study and related prescription medications were collected for the entire study period.

Eligibility criteria:
inclusion criteria: * healthy japanese aged 6 months to 19 years exclusion criteria: * history of anaphylaxis, serious vaccine reactions, hypersensitivity to vaccine viral proteins or excipients * administration of adjuvanted influenza vaccine or suspected influenza disease within 3 month prior to study start * administration of any other vaccines within 4 weeks prior to enrollment expect for seasonal influenza vaccines within 1 week * history of progressive or severe neurological disorders

Keywords: influenza a h1n1 subtype children/adolescent vaccine adjuvant
the application of internet+ home-based cardiac rehabilitation in atrial fibrillation patients after rfca

Conditions: Atrial Fibrillation; Cardiac Rehabilitation

Summary: epidemiological reports show that the incidence of atrial fibrillation continues to increase. af is the most common arrhythmia with high mortality and disability rate. radio frequency ablation has good therapeutic effect of af symptoms. however, even after successful radio frequency ablation, there are still many discomforts that deserve medical attention. the benefits of cardiac rehabilitation for patients with heart disease have been recognized，but the adherence with cardiac rehabilitation is not satisfactory. home-based rehabilitation has received increasing recognition because it has overcome many obstacles for patients to participate in cardiac rehabilitation. the application of internet+ follow-up mode and intelligent wearable devices provide new ideas for home-based cardiac rehabilitation with the progress of information technology nowadays. this study used an experimental research design. the aim was to explore the application effects of internet platform and wearable devices in home-based cardiac rehabilitation in patients with atrial fibrillation after radio frequency ablation. the final goal is to provide the basis for the development and application of this kind of home-based cardiac rehabilitation care in patients with atrial fibrillation after radio frequency ablation.


Eligibility criteria:
inclusion criteria: * patients diagnosed with atrial fibrillation and planned for treatment with radiofrequency catheter ablation (rfa) for af; * patients with age from 18 to 75 years; * patients or primary caregiver are able to use smartphones; * providing oral and written informed consent. exclusion criteria: * radiofrequency ablation was not performed for various reasons; * patients who were unable to understand the study due to severe cognitive impairment; * patients with psychiatric disorders; * patients with serious and instable body or severe complications; * patients sufferring other exercise contraincations.
an act-enhanced weight management and fitness program for navy personnel

Conditions: Obesity; Overweight

Summary: the proposed study is a cohort-randomized controlled trial of acceptance and commitment therapy-enhanced shipshape (act+ss) compared to the standard shipshape-only program, for overweight or obese navy personnel. as a result of covid-19, this study is now being conducted virtually.

the proposed study is a cohort-randomized controlled trial of act-enhanced ss (act+ss) compared to the ss-only program. cohorts of navy personnel who are failing or at risk of failing the body composition assessment (bca) or who are overweight/obese will be randomized to receive 8 weekly act+ss intervention groups or 8 weekly ss-only intervention groups. the scientific aims are to: 1) determine the effectiveness of act+ss compared to the ss-only program; 2) examine psychological flexibility as a mechanism underlying intervention response; and 3) explore potential moderators of intervention response. the primary outcome is weight loss. secondary outcomes include bmi, body fat %, indices of physical activity, problem eating, functioning and quality of life, emotional functioning and indices of psychological flexibility, measured at baseline, mid- and post-intervention, and 3- and 6-month follow-up and self- reported bca status at 6-month follow-up. the investigators have purposefully designed a cohort-randomized trial with interventions that are pragmatically implemented in a real-life military setting, and outcomes that are immediately relevant to service members and leadership. the cohort randomization is essential to the feasibility and acceptability of the research in this setting. the military-relevant and generalizable findings are more likely to have impact within the military. ss provides an ideal comparison arm that is the current standard of practice in the navy. integrating act with ss in this setting overcomes many of the logistical, practical, chain-of-command, and other challenges that have typically impeded research in the military. the investigators have thoughtfully selected primary and secondary outcomes that are theoretically linked, and additional assessments that are empirically-based and will allow better understanding of mediators and moderators of intervention response in navy personnel. due to covid-19 we have adapted the interventions to be administered virtually.

Eligibility criteria:
inclusion criteria: * navy personnel who are overweight/obese or have failed or are at risk of failing the bca * 18-69 years of age * willingness to participate in the study exclusion criteria: * any physical limitations (injuries, pregnancy, etc.) that preclude engagement in the physical fitness activities

Keywords: obesity military acceptance and commitment therapy overweight weight-management navy personnel fitness
effect of omega-3 index on cellular metabolism and quality of life

Conditions: Healthy

Summary: determine whether personal optimization of the omega-3 index improves cellular metabolism and quality of life (according to the sf-36 form).


Eligibility criteria:
inclusion criteria: * participant aged 19 or over * available for the entire duration of the study and willing to participate on the basis of the information provided in the fiu duly read and signed. exclusion criteria: * allergy known to fish * pregnant women who breast-feed or test positive for pregnancy

Keywords: omega-3 index cellular metabolism epa monoglyceride quality of life
risk and prevention study: evaluation of the efficacy of n-3 pufa in subjects at high cardiovascular risk

Conditions: Cardiovascular Diseases

Summary: in the everyday practice cardiovascular prevention in people at high risk is still unsatisfactory and treatments with documented efficacy are generally under-used. polyunsaturated fatty acids of marine origin (n-3 pufa) are the latest more promising strategy to improve prognosis in these patients. the risk and prevention study combines an epidemiological and an experimental approach in order to: 1. verify the possibility to optimise cardiovascular prevention in subjects at high risk by planning the intervention with patients and setting individual goals (outcome study) 2. evaluate the efficacy of a long term n-3 pufa treatment in reducing the incidence of cardiovascular events, through a controlled, randomised, double blind clinical trial.


Eligibility criteria:
inclusion criteria: * multiple risk factors: * diabetes, * age =\> 65 years, * male sex, * hypertension, * hypercholesterolemia, * smoking, * obesity, * family history of premature cardiovascular disease; * previous manifestations of atherosclerotic disease (ischemic stoke, transient ischemic attack \[tia\], peripheral artery disease, previous arterial revascularisation procedures, angina pectoris) exclusion criteria: * contraindications (known allergies to n-3 pufa) or indications (previous myocardial infarction) for the treatment with n-3 pufa * serious comorbidity with an unfavourable prognosis over the short term * expected non compliance over a long period of time * pregnancy

Keywords: cardiovascular risk cardiovascular diseases cardiovascular prevention polyunsaturated fatty acids diabetes hypertension hypercholesterolemia obesity
prophylactic antibiotics in comatose survivors of out-of-hospital cardiac arrest

Conditions: Out-of-hospital Cardiac Arrest

Summary: the purpose of this study is to determine whether there is potential benefits of prophylactic antibiotic treatment in comatose survivors of out-of-hospital cardiac arrest (ohca) treated in intensive care unit with therapeutic hypothermia.

postresuscitation management of comatose survivors of out-of-hospital cardiac arrest (ohca) significantly improved and "bundle of care" including therapeutic hypothermia, immediate coronary angiography, percutaneous coronary intervention (pci) and contemporary intensive care nowadays leads to survival with good neurological recovery. benefit of prophylactic antibiotics, which may suppress development of postresuscitation infection and especially early onset pneumonia and thereby decrease the severity of postresuscitation systemic inflammatory response, is controversial. because of these uncertainties, the investigators performed a single-center randomized clinical trial comparing prophylactic versus clinically-driven administration of antibiotics in comatose survivors of ohca. the investigators hypothesized that prophylactic antibiotics may decrease the severity of postresuscitation systemic inflammatory response by reducing the incidence of postresuscitation infection and especially pneumonia which was further addressed by repeat microbiological sampling.

Eligibility criteria:
inclusion criteria: * female and male over 18 years old * comatose survivors of out-of-hospital cardiac arrest treated in intensive care unit with therapeutic hypothermia exclusion criteria: * suspected or confirmed pregnancy * allergy to amoxicillin-clavulanic acid * tracheobronchial aspiration * antibiotic therapy before cardiac arrest * need of antibiotics due to other causes * candidates for immediate veno-arterial extracorporeal membrane oxygenation (va ecmo) * patients in whom no active treatment was decided on admission

Keywords: out-of-hospital cardiac arrest prophylactic antibiotics
chemotherapy related anemia

Conditions: Anemia; Non-Myeloid Malignancies

Summary: this study is investigating darbepoetin alfa for the treatment of anemia in patients with non-myeloid cancers who are receiving chemotherapy. darbepoetin alfa is a recombinant protein that stimulates the production of red blood cells. in this study, darbepoetin alfa will be administered as either an injection under the skin (subcutaneously) or directly into a vein (intravenously).


Eligibility criteria:
inclusion criteria: * diagnosed with a non-myeloid malignancy * scheduled to receive a minimum of an additional 12 weeks of chemotherapy from the time of first dose of study drug * screening hemoglobin concentration less than or equal to 11.0g/dl * ecog performance status of 0 to 2 * adequate renal and liver function exclusion criteria: * history of seizure disorder * received recombinant human erythropoietin (rhuepo) or darbepoetin alfa therapy within 4 weeks before study day 1 * more than 2 red blood cell transfusions within 4 weeks before study day 1, or any red blood cell transfusion within 14 days before study day 1
wireless, intermittent monitoring of right heart pressures in hf

Conditions: NYHA Class III Heart Failure

Summary: the purpose of the trial is to evaluate the wireless monitoring of pulmonary artery pressure using the cardiomems hf pressure measurement system in adult subjects with nyha class iii heart failure.

the trial is designed to demonstrate that the cardiomems sensor can be positioned in the right or left pulmonary artery, and that sensor pressure measurements correlate to standardized methods of intra-cardiac pressure measurements post-sensor implant and at the 60 day visit. safety will be monitored by the occurrence of adverse events throughout the trial.

Eligibility criteria:
inclusion criteria: 1. subject is male or female, at least 18 years of age 2. subjects of childbearing age who have a negative serum pregnancy test, and at screening have agreed to use a reliable mechanical or hormonal form of conception during the study. 3. subject has a diagnosis of new york heart association (nyha) class iii hf at screening and at baseline. 4. subject is able and willing to provide written informed consent or the subject guardian is able and willing to provide informed consent. 5. subject has life expectancy of 1-2 years. exclusion criteria: 1. subject has unstable medical condition or impairment other than a medical condition associated with hf which would significantly increase the subject's morbidity or mortality risk. 2. subject is unable to tolerate a right heart catheterization. 3. subject is planned to undergo a heart transplantation or cardiac surgery within 2 months after enrollment. 4. subject has permanent indwelling central venous catheter. 5. subject has history of myocardial infarction (mi), unstable angina, stroke, transient ischemic attack, or intractable arrhythmias within last 2 months. 6. subject has history of congenital heart disease or prosthetic valve on right side. 7. subject has unstable hypertension. 8. subject has a known coagulability disease state. 9. subject has a known hypersensitivity and/or allergy to aspirin and clopidogrel. 10. subject has active lung infection or acute pulmonary decompensation. 11. subject has elevated white blood cell count and signs of infection are evident. 12. subject has chronic renal insufficiency as defined by serum creatinine of greater than or equal to 2 mg/dl or requirement for dialysis. 13. subject who is pregnant or lactating or might become pregnant during the duration of the study. 14. subject who is participating in another therapeutic interventional trial. 15. subject has other medical, psychological, or social circumstances that may affect the ability to comply with the study requirements or increase risk to the subject.
risk factor analysis of chewing and swallowing performance in geriatrics

Conditions: Swallowing Disorder; Chewing Problem; Geriatrics

Summary: various structural and functional problems in neural, sensory and perceptual, cardiovascular, pulmonary, gastrointestinal, endocrine, and musculoskeletal systems occur in geriatrics not associated with a specific disease. one of the problems observed in geriatrics is chewing and swallowing disorders. failure to detect changes in chewing and swallowing performance in elderly individuals at an early stage may lead to chewing and swallowing disorders and serious complications in later stages. therefore, it is necessary to comprehensively and systematically address the possible factors affecting chewing and swallowing performance in geriatric individuals. the first aim of the study is to analyze the factors affecting chewing and swallowing performance in geriatric individuals within the scope of the international classification of functioning, disability, and health (icf). the second aim of the study is to create a dysphagia risk prediction model for geriatric individuals based on the results of the analyses to be conducted. in the study, the dependent variables, chewing performance, will be evaluated with the chewing and swallowing test of solids, and swallowing performance will be assessed with the repetitive saliva swallowing test and dysphagia limit. independent variables affecting chewing and swallowing performance have been considered within the scope of the icf, and all possible factors determined for both geriatrics and swallowing have been listed, and the evaluation parameters and assessment tools have been decided. the evaluation parameters have been categorized under icf headings such as personal factors, body structures, body functions, activity and participation, and environmental factors, and the evaluations to be conducted have been divided into two groups: geriatric and physiotherapy evaluations. the geriatric evaluations are part of routine geriatric assessment and do not include any specific evaluation for the study. physiotherapy evaluations will be applied in a certain order to use time efficiently and will take approximately 35-45 minutes. through geriatric and physiotherapy evaluations, a holistic assessment of participants within the scope of icf will be ensured.


Eligibility criteria:
inclusion criteria: * being voluntary to participation, * being over 65 years old, * understanding and following simple instructions, * being able to walk independently for 4 meters. exclusion criteria: * having a problem that prevents communication and/or following simple instructions.

Keywords: swallow chewing geriatrics risk factor
tiva versus desfluran anaesthesia in patients undergoing bariatric surgery

Conditions: Total Intravenous Anesthesia; Desflurane; Obesity; Pain, Postoperative; Nausea, Postoperative

Summary: many factors during laparascopic surgery leads to ponv (postoperative nausea and vomiting), such as c02 insufflations causing peritoneal stretch and irritation and type of anaesthesia given during surgery. the two anesthetic techniques used in bariatric surgery are gas anesthesia (remifentanil tci and desfluran) and total intra venous anesthesia (tiva) with propofol. there are studies which have shown a reduction in postoperative nausea and vomiting following tiva, and there are publications showing no statistically significant difference. the aim of this study was to investigate the best anaesthetic approach for obese subjects, evaluating awakening time, postoperative nausea and pain. our hypothesis was based on the fact that propofol is a lipid-soluble anesthetic and therefore might have a prolonged effect in obese patients, leading to a longer awakening time along with postoperative nausea and vomiting. this hypothesis is also described earlier by obese patients have more depots (bulk fat) and also more fat surface making anaesthetics storage more easier, and also that the anesthetic will return into the circulation when the administration is stopped \[18\].


Eligibility criteria:
inclusion criteria: * bmi ≥35 kg/m2 with at least one comorbid condition or bmi ≥40 kg/m2. exclusion criteria: * drug abuse * severe mental illness * age\<18 * serious medical condition; cancer, end-stage lung disease (asa\>3) or allergies to any drugs used in the study